Brain Cancer
7 videos · last 6 months shuffled daily, then older videos newest first
▶
56:40 Dan Otap on Sites, Compliance and Industry Roles
Dan Otap, Alliance & Partnerships Director at Genentech, discusses his path from brain tumor trials and regulatory compliance at Columbia University to community access trials, on the Note to File podcast.
▶
50:30 RANO Assessment: Reduce Variability in Glioblastoma Trials
Gerry Thompson, FRCR, PhD, demonstrates a digital RANO workflow in a QMENTA webinar for assessing treatment response across longitudinal glioblastoma scans, including lesion tracking, response calculations and reader adjudication.
▶
3:14 Black Diamond Therapeutics BDTX-1535
Matthew Lucas, PhD, Black Diamond Therapeutics, Cambridge, MA, talks on BDTX-1535, an inhibitor of selected EGFR mutations in non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM).
▶
45:21 PET RANO 1.0 for Response Assessment in Glioma Trials
Veronika Matsuk, PhD, an oncology clinical scientist, presents PET RANO 1.0, a consensus framework for standardising amino-acid PET assessment of metabolic response and progression in diffuse glioma trials and where MRI criteria fall short, for MERIT CRO.
▶
3:56 A Doctor’s Perspective on IN8bio’s Trial Results
Dr. Burt Nabors of UAB discusses IN8bio's gamma-delta T cell trial results in glioblastoma and how the approach differs from others.
▶
21:57 Key Decisions in Developing CNS Oncology Medicines
Lantern Pharma CEO Panna Sharma and board member Dr. Lee Schalop, co-founder of Oncoceutics, discuss indication selection, trial design and the STAR-001 program in CNS cancers, drawing on Schalop's work developing ONC201 (dordaviprone).
▶
16:13 INOVIO DNA Immunotherapy and GBM
Dr. Jeffrey Skolnik, Inovio's VP of Clinical Development, Oncology, talks to Dr. David Reardon of Dana-Farber, coordinating principal investigator of GBM-001/INO-5401, about DNA immunotherapy in glioblastoma.